welcome junkmasterg,
should be an intersting ride....I hope it's fun and not scary

There sure is alot of trading going on today

there was a runup to over $3, by a pumper/dumper named bigdog around 2000

http://quotes.nasdaq.com/quote.dll?page=charting&mode=basics&intraday=off&timeframe=5y&a...

the past couple of press releases and SHM have mentioned

1) Jesup and Lamont (same guy as the old red fox show)- as finacial gurus and placement agents.

2) Expansion - doesn't necessarily mean hiring new people....

3) the topic of delivery has breen brought up many times

4) An old press release mentioned Biozone

1 + 2 + 3 + 4= 5} this is purely speculation, I am just tying all things together, but maybe 5) CYGX gets funding from 1, to do 2, to handle 4, taking care of 3.

Like arnold says, anything is possible

I agree,
and the collaboration with Biozone started about then....

Anyone else see where this is heading?

I agree, they seem to not have anything to do with main science, but if you go to their website and click on the link for pubilcations, they have a long list of articles outside of the test kits they sell....it may be they just fund researchers a little (like 10,000 or so) and get their name on papers. As you can see, the NIH is the other funding agency, I am sure the majority comes from them

But I am pretty sure CYGX has nothing to do with them

not much, I don't think they are the same company

http://www.biozonelabs.com/

and


http://www.biosan.com/

That is why I posted the Biozone collaboration from the press release from last august....

no more LO....Ignore and he will go....

would anyone else like to comment on mkwmike's qurestion regarding the science?

is Doc still around?

my guess is within 24 hours, the transfection/delivery of the construct ranges from an hour to 4 (max), then the ssDNA needs to be made...There should be enough made in the 24 hour period to silence whatever is targeted.

Suky, maybe you can contact the lead researcher and suggest they call the company

looks like someone just dumped alot

Holycow,
there is nothing wrong with Money, that is why we are here...especially with 2 kids, I would REALY like this to go to $$$$$$$ instead of $$$

holycow...don't get me wrong....I believe in your vision...moreso the company's vision....I too ultimately want to help people.

obviously, they had a delivery problem too.

Thanks suky, I am sure you will report anything new that malcolm has to say.....

holy,
No disrespect intended to you or Skooby,
but this is a OTCBB stock, penny at that (so far)...you are starting to sound hypnotized....a group mentality does not make the stock any better....(I SAY AGAIN...I LOVE CYGX...NO BASH INTENDED TO YOU OR SKOOBY). Everyone should do their own DD, I really like when the poster said (I forget who and am too lazy to look it up)...."if you don't understand the technology, don't invest in the technology". So, I understand the sentiment that you feel towards the stock, but please temper it somewhat....(I know it is tough to control, I too feel it, but try to keep it in check) Thanks.

I would further say, if you don't like the management, you can always go somewhere else with your money.....I hold no grudge towards blasher....he felt he would make money elsewhere, that is his right....he will come back.

dear all, I don't like to use the analogy of anything coming out of a goose, and I definetly don't want to see it.

Again for the delivery, the issue of IV over IM/IP is of slight interest, but moreso, the formulation of the vector is the important part. On the CYGX website, it mentions that they are toying with lipid formulation etc.... My guess, they are using some liposomal vector for delivery of the ssDNA vector.....maybe a proprietary formulation, or working with Biozone on their proprietary lipid vectors.....

here is the press release from Aug 2003

CytoGenix and BioZone Laboratories Initiate Cooperative Alliance
Houston, TX, (August 5, 2003) Cytogenix, Inc. (OTCBB: CYGX)

CytoGenix (CYGX:OTCBB) has completed an Agreement with BioZone Laboratories, Inc. of Pittsburg, California, to investigate the synergy of their technologies in order to develop and test new formulations for select therapeutic categories.

As part of this alliance the two companies will use BioZone's proprietary liposome technology, QuSomes™ to microscopically encapsulate CytoGenix' ssDNA expression system sequences and protect them from metabolic destruction by exo- and endo-nucleases found on the skin and in the bloodstream. QuSomes™ are composed of a combination of lipids and lipid derivatives that serve as the envelope and delivery vehicle for the plasmid DNA. They also allow more uptake of ssDNA by the cell, and better release of ssDNA inside the cell.

Dr. Sangita Ghosh, Senior Scientist and Director of Research and Development at BioZone noted that this is an excellent blending of technologies. "We're confident that the use of our liposomal system will significantly enhance the delivery and uptake of the plasmids comprising the CytoGenix Expression Vector, which will result in higher levels of production of the desired DNA sequence within the cells", she said.

"The Agreement with with BioZone represents another step in the CytoGenix strategy directed at targeting a larger class of cells," said CytoGenix CEO, Dr. Malcolm Skolnick. "We believe BioZone’s QuSome™ technology will improve efficiency in the topical formulations we have developed as well as provide delivery capabilities that enable systemic application of our ssDNA expression system technology."

BioZone Laboratories is a biopharmaceutical company that develops, manufactures and markets drug delivery systems, which enhance the performance and can limit the side effects, of drugs. BioZone was just granted a US patent for a new liposomal delivery system they believe will revolutionize liposome, and micro-encapsulation delivery. This new system called QuSomesTM was developed to encapsulate a variety of drugs, proteins and peptides at a fraction of the cost of conventional liposomes. There are several commercially successful drugs that have been formulated with liposomes and have proven to be more effective in treating diseases with fewer side effects than traditional drug formulations.

CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative products and services based on its proprietary DNA expression technology. CytoGenix has products in pre-clinical development including, anti-herpes, anti-psoriasis and anti-inflammatory topical creams. The company owns a US patent for its core DNA expression technology and has 40 international or US pending patent applications.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be
company.....

blasher, I think he meant that with you done selling, there is a upswing in the ask...people are not willing to sell at lower price, people forced to buy higher, will give the upswing...I don't think he was calling you a basher.....

IV over IM- especially with sepsis, gives the "drug" a faster distribution and if the bacteria are in the blood...then there you go....

Now, again, can anyone please comment on the value of the Dutton report? how does it influence the market if at all? What is the exposure of the report? etc..

Thanks

To all,
I will no longer be moderator for this board. Matt is the overseer, if you have problems IM Matt. I put LO on ignore, and suggest if you have a problem with LO, put him on Ignore too.

News Room > News@MSKCC > News 2003 Issues > October 2003 News@MSKCC > Antisense Therapy Shrinks Pancreatic Tumors in Mice


Antisense Therapy Shrinks Pancreatic Tumors in Mice


NEW YORK, October 20, 2003 -Research by scientists at Memorial Sloan-Kettering Cancer Center (MSKCC) describes a new treatment that significantly shrank human pancreatic tumors that were grown in mice, without apparent toxicity. The work is published in the October issue of Nature Medicine.

The researchers used AS-ODN, an "antisense" drug made of short strands of DNA, to specifically inactivate Kinase Suppressor of Ras, a key protein on the cellular pathway that signals tumor cell growth by a gene called Ras. Inactivation of Kinase Suppressor of Ras leaves intact other Ras functions necessary for normal cell operation.

Unregulated cell growth is a defining characteristic of cancer, which can develop when Ras genes are defective. "A majority of pancreatic cancers contain a common mutation in Ras, making it an attractive molecular target for therapeutic intervention," said senior author Richard Kolesnick, MD, head of the MSKCC Signal Transduction Laboratory.

Pancreatic cancer is known for being difficult to treat because there are often no symptoms early on and it is usually detected in its advanced stages. Each year about 28,000 Americans are affected with this disease, which currently lacks effective therapies.

"We are currently planning a Phase I clinical trial of antisense therapy with AS-ODN in patients with pancreatic cancer," said study co-author Zvi Fuks, MD, Deputy Physician in Chief for Planning at MSKCC.

The work is a major focus of the MSKCC Experimental Therapeutics Center, a multi-disciplinary, multi-departmental program that promotes and facilitates the development of new cancer therapies from the lab bench to the bedside. It helped fund the study in addition to support from the National Institutes of Health.

The study's co-authors include H. Rosie Xing; Carlos Cordon-Cardo; Sinzhu Deng; William Tong; and Luis Campodonico, all of whom are at MSKCC.

MSKCC is the world's oldest and largest institution devoted to prevention, patient care, research and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose and treat cancer. Our specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide.




WOULD YOU LIKE MORE?

Intracisternal Antisense Oligodeoxynucleotides to the Thyrotropin-Releasing Hormone Receptor Blocked Vagal-Dependent Stimulation of Gastric Emptying Induced by Acute Cold in Rats1
V. Martinez2, S. V. Wu and Y. Taché

Cold exposure increases TRH gene expression in hypothalamic and raphe nuclei and results in a vagal activation of gastric function. We investigated the role of medullary TRH receptors in cold (4–6 C, 90 min)-induced stimulation of gastric motor function in fasted conscious rats using intracisternal injections of TRH receptor (TRHr) antisense oligodeoxynucleotides (100 µg twice, -48 and -24 h). The gastric emptying of a methyl-cellulose solution was assessed by the phenol red method. TRH (0.1 µg) or the somatostatin subtype 5-preferring analog, BIM-23052 (1 µg), injected intracisternally increased basal gastric emptying by 34% and 47%, respectively. TRHr antisense, which had no effect on basal emptying, blocked TRH action but did not influence that of BIM-23052. Cold exposure increased gastric emptying by 64%, and the response was inhibited by vagotomy, atropine (0.1 mg/kg, ip), and TRHr antisense (intracisternally). Saline or mismatched oligodeoxynucleotides, injected intracisternally under similar conditions, did not alter the enhanced gastric emptying induced by cold or intracisternal injection of TRH or BIM-23052. These results indicate that TRH receptor activation in the brain stem mediates acute cold-induced vagal cholinergic stimulation of gastric transit, and that medullary TRH may play a role in the autonomic visceral responses to acute cold.

Thanks Tatonkano,
I saw it earlier, but my question refered to the importance of this report. I want to stress again, I am not a business guy, just a science guy....how much credibility does JM Dutton have? How will it affect the market in general? etc...

renshen, listen to Malcolm Skolnick on American Scene....go to Suky's CYGX-links (posted earlier)-listen to the program.....successfull delivery I.M. AND I.V.


and Larry, as far as you having too much class to call names...try rereading your posts...unless matt has erased them for being to vulgar.

yes, but the detailed quote is up to date....

excuse me, but I believe they are talking about R-N-A--you even posted it yourself....

so, what does this mean for the company?

NICE!!!!!!!!!!!!!

I take it, it is a good sign when all except one Level II quote have increased with a green arrow? We should be moving up.

suky, did he happen to mention in what animal? what formulation? etc...? I can't wait for the publication.


Anyone have an idea what the ceiling is (for resistance)?

I hope everyone had a great 4th, It and the great posts this weekend have lifted my spirits, and am now ready for the rest of the year.....

Well said Paulness,
Happy 4th everyone, and yes, I do mean EVErYONE

with the trades as they haveoccured today, would it be correct to say that very few are willing to sell at the bid? so, more people are holding?

congrats....then just a slow day, getting ready for the weekend....and as a note to everyone, as moderator, I still only get 18 posts....

Hogger,

Did CYGX talk at all about India and what is going on there?

Arnold,
who is your broker/service? Can they say if it is halted?

It is intersting that with the increase in volume the past couple of days, there seems to be no volume today. Any hints as to why? And LO, please do not bother.

I do not think I have the power to kick LO off the board, just remove his posts...I will use that power wisely, only when he attacks, puts up lies, and posts nonsense....

Great, NOW what do I do?

I know Spiffy,
but I really don't like people who put words in my mouth. He is calling me a liar and a pumper when all I have done was state facts from press releases and interviews. I am hoping the guardian of the board will see him for who he is, a person with a vendetta against the company or a basher. I am hoping he gets banned.

People can have differences of opinions, but he attacks and attacks.

I had him on ignore, but just wanted to check on him....but he is back on Iggy.

Along the ICAM front- potential link in atherosclerosis, epecially with the increase in obesity in this country ( have to admit, I am helping out that statistic more than I want to) could be another avenue of research.